 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...5859606162636465666768...123124» |
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Efficacy and safety of transcatheter arterial chemoembolization in combination with camrelizumab and targeted agents in intermediate-stage unresectable hepatocellular carcinoma: A single-arm, prospective, real-world study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6088;
In this single-arm, prospective, real-world study, patients with intermediate-stage unresectable HCC who had a Child-Pugh score ≤ 7 and had not received prior systemic anti-cancer treatment would receive comprehensive treatment with TACE followed by immunotherapy with camrelizumab 200 mg every 3 weeks plus a tyrosine kinase inhibitor (TKI) agent selected from lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight < 60 kg), sorafenib 400 mg twice-daily or donafenib 200 mg twice-daily until intolerable toxicity or disease progression. TACE combined with camrelizumab plus targeted therapy in the treatment of advanced HCC shows good efficacy in controlling tumor progression and may provide opportunity of resection.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., lenvatinib / Generic mfg.
Lenvatinib combined with hepatic arterial infusion of modified FOLFOX regime as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6086;
Lenvatinib combined with FOLFOX-HAIC was well tolerated and had shown promising ORR, PFS rates in patients with intermediate-stage HCC beyond up-to-seven criteria. A prospective large-scale trial is needed to justify these results.
- Stivarga (regorafenib) / Bayer
A retrospective study on the efficacy and safety of regorafenib or regorafenib combined with immune-checkpoint-inhibitors (ICIs) after first-line therapy in patients with advanced hepatocellular carcinoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6063;
Regorafenib combined with ICIs is recommended as early as second-line therapy to benefit patients. Different regimens of first-line therapy have no effect on PFS in second-line therapy.
- Stivarga (regorafenib) / Bayer
Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma (HCC): A retrospective, real-world study in China. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6061;
The preliminary results of this retrospective real-world study, indicate that regorafenib combined with pd-1 therapy as second-line treatment provide clinical benefits in uHCC patients with a manageable toxicity in Chinese patients. Data will be further collected to reduce bias caused by small sample size and baseline differences.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib as first-line treatment and followed by tyrosine kinase inhibitors (TKIs) combined with PD-1 blockades regimen after disease progression for advanced hepatocellular carcinoma (HCC): A real-world exploratory study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6059;
The present study indicated that anlotinib as first-line treatment and followed by TKIs combined with PD-1 blockades regimen after disease progression for advanced HCC exhibited potential efficacy and tolerable safety profile in real-world setting. The conclusion should be validated in more pts included subsequently.
- Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6052;
P=N/A
This real-world study of lenvatinib plus PD-1 inhibitors achieved long survival and considerable ORR for uHCC patients in China. The tolerability of combination therapy was acceptable but should be still monitored closely.
- nofazinlimab (CS1003) / CStone Pharma, EQRx
Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6043;
P1a/1b, P3
The PFS is longer and the ORR is higher compared to the data previously reported, which support further development as a combination treatment for improving outcomes in uHCC pts. The ongoing multi-regional, double-blinded, randomized, placebo-controlled, phase 3 trial (CS1003-305, NCT04194775) is currently recruiting and will further evaluate adding CS1003 to LEN as a 1L treatment in uHCC.
- lenvatinib / Generic mfg.
Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience. (Available On Demand; 211) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5658;
Lenvatinib was used as a second line for 52% of pts, mainly starting from 14 mg/daily (n=20, 69%) and one pts with concomitant pembrolizumab. We confirm the activity of lenvatinib in pts with advanced or metastatic T and TC, despite the use of lower doses than the phase 2 study.
- Keytruda (pembrolizumab) / Merck (MSD)
Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. (Available On Demand; 463) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5415;
P3
Pts with aEC and 1 prior platinum-based chemotherapy regimen (or up to 2 if 1 was given in neoadjuvant/adjuvant setting) were randomized (1:1) to receive LEN 20 mg orally QD + pembro 200 mg IV Q3W or TPC (doxorubicin at 60 mg/m2 IV Q3W or paclitaxel at 80 mg/m2 IV QW [3 weeks on; 1 week off]). Clinically meaningful improvements in PFS2 were seen in the LEN + pembro group compared with TPC in pMMR and all-comer pts.
- Avastin (bevacizumab) / Roche, Rubraca (rucaparib) / Clovis, Tecentriq (atezolizumab) / Roche
An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3774;
P2
The combination of rucaparib, bevacizumab, and atezolizumab may safely be used to treat recurrent/persistent endometrial cancer. This combination demonstrates clinically meaningful improvement in response, with acceptable toxicity.
- Keytruda (pembrolizumab) / Merck (MSD)
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma. (Available On Demand; 489a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3160;
P2
On-treatment biopsy and blood samples will be required for correlative assessments. Accrual in all cohorts is ongoing.
- Votrient (pazopanib) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Checkpoint inhibitor and multireceptor tyrosine kinase inhibitor combination in relapsed refractory sarcomas: A single institution series. (Available On Demand; 434) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3102;
The overall survival is more than historical controls for initial metastatic ASPS, initial metastatic EWS, and recurrent metastatic OST. Our report will inform colleagues about the potential of CPI/TKI combination for these patients with few options.
- Halaven (eribulin mesylate) / Eisai
A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3077;
P1/2
L at 14mg (vs 18mg) had a better AE profile without compromising activity. Future randomized study to confirm the efficacy of the combination is warranted.
- Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. (Available On Demand; 67) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2845;
Chylous effusions can emerge on treatment with certain MKIs or selective RET TKIs. Recognition of this potential side effect is key to prevent misattribution of worsening effusions to progressive malignancy and to motivate a better understanding of its biology and management.
- Toxicities of anti-VEGF therapies used in metastatic renal cell carcinoma: A real-world experience. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2567;
Cabozantinib has most reported GI AEs and sunitinib has most reported ONJ, SHTN, QT prolongation, arrhythmias, and aortic complications. With expanding treatment landscape for mRCC, this study helps shed light on the different anti-VEGF toxicity profiles and would therefore support treatment decision making.
- Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study. (Available On Demand; 36) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2475;
Optimal management of nccRCC remains an unmet need and prospective data is warranted to guide treatment selection for this population. >n- number of patients; mo.-months; NA-not available.
- Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations. (Available On Demand; 27) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2466;
In patients receiving 1st line IO/IO or TKI/IO, ORR2nd was higher with IO/IO and median PFS-2 was numerically higher with TKI/IO, but no statistically significant difference in PFS-2 or OS was seen. These findings suggest that IO/IO and TKI/O are both acceptable 1st line treatment strategies in ccRCC.
- First-line therapy for elderly patients with advanced renal cell carcinoma (aRCC): A systemic review and network meta-analysis. (Available On Demand; 23) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2462;
Pem + Len showed improved PFS compared with Pem + Axi, but no difference compared with Niv + Cab or Cab alone. Further validation using real-world data is needed to confirm the efficacy and safety of first-line regimens for the geriatric population with aRCC.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. (Available On Demand; 6) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2430;
P3
These findings remained consistent after accounting for subsequent therapies, as evidenced by prolonged PFS2 and adjusted OS. Results further support LEN + PEMBRO as a standard of care in 1L aRCC.
- lenvatinib / Generic mfg.
Real-world analysis of use of lenvatinib in differentiated thyroid cancers. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2408;
Results further support LEN + PEMBRO as a standard of care in 1L aRCC. In the real world lenvatinib provides a 2 year PFS and OS of 29.3% and 38.8% which is lower than that reported in the pivotal SELECT study.
- Mekinist (trametinib) / Novartis, Tafinlar (dabrafenib) / Novartis
Improved laryngeal function after neoadjuvant therapy for advanced thyroid cancer: A potential outcome of interest for future clinical trials. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2397;
Additionally, neoadjuvant therapy resulted in tumor response sufficient to spare 5 RLNs from surgical resection (83%). Serial laryngoscopic exams during neoadjuvant therapy could guide surgical strategy, impact surgical timing, and provide an additional meaningful treatment outcome.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib in radioactive iodine-refractory differentiated thyroid cancer and the usefulness of SUVmax as an prognostic indicator. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2383;
This study confirmed the efficacy of Anlotinib with a high disease control rate. SUVmax can be used as an indicator to predict the therapeutic effect of Anlotinib in RAIR-DTC patients.
- Keytruda (pembrolizumab) / Merck (MSD)
A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies. (Available On Demand; 95b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2344;
P2
Response assessments will occur every 3 cycles. Enrollment began July 2021 and 16 of the planned 45 patients (ACC cohort 9 of 20 pts, non-ACC 7 of 25) have been accrued.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy. (Available On Demand; 75) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2317;
P3
In the extended follow-up, C maintained its superior PFS vs P irrespective of prior L and/or S. AEs in each subgroup were consistent with that of the overall population. This is also the first phase 3 study demonstrating a clinical benefit with C after prior L in RAIR DTC pts.
- lenvatinib / Generic mfg.
Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2226;
P2
The median RFS was longer than our historical data (mRFS = 9.03 months), and these findings warrant further investigation in a controlled study. Funding: Eisai Co., Ltd.
- Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2195;
Both TOS and ROS in lenvatinib group are better than those in sorafenib group. The possible mechanisms was that EGFR activation limits the response of HCC cells to lenvatinib.
- lenvatinib / Generic mfg.
The value of pretreatment 18F-FDG PET/CT to predict the pathological treatment response of hepatocellular carcinoma patients treated with PD-1 inhibitors and lenvatinib as a conversion therapy in BCLC stage C. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2186;
The possible mechanisms was that EGFR activation limits the response of HCC cells to lenvatinib. The TLR may be a powerful marker to predict the PTR of HCC patients with BCLC stage C who treated with PD-1 inhibitors and lenvatinib as a conversion therapy.
- Opdivo (nivolumab) / Ono Pharma, BMS
Immunotherapy with nivolumab after progression on lenvatinib in advanced hepatocellular carcinoma: A real-world Indian experience. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2150;
There were few patients who showed durable response, but there are no biomarkers to choose these patients. The immune related side effects were manageable.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., lenvatinib / Generic mfg.
Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime(FOHAIC) in patients with BCLC stage C hepatocellular carcinoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2112;
This study demonstrated that lenvatinib plus FOHAIC had acceptable toxic effects and shown promising ORR, PFS and OS in BCLC stage C hepatocellular carcinoma. Warrants its further investigation in a large-scale trial.
- Addition of tyrosine kinase inhibitors (TKIs) in patients (pts) with unresectable hepatocellular carcinoma (HCC) who progress on first-line immunotherapy (IO). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2095;
TKIs added were lenvatinib (44/46) and sorafenib (2)... Adding a TKI after PD on single agent IO in pts with advanced HCC did not add a signal of clinical benefit compared with reported outcomes from second-line TKIs alone.
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
Clinical impact of the changes of muscle volume during various systemic therapies in patients with unresectable hepatocellular carcinoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2080;
The decrease of muscle volume at 6-14W was significantly associated with PFS in patients treated with ATE+BEV, while pretreatment sarcopenia was not a significant factor. Monitoring muscle volume during immunotherapy would be useful in clinical practice.
- lenvatinib / Generic mfg.
The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2079;
In conclusion, lenvatinib plus anti-PD-1 showed a favorable efficacy and controllable safety for u-HCC patients in real-world practice. The absolute improvement of the 12-month survival rate with combination therapy was more substantial in patients with major vascular invasion or extrahepatic spread and Child-Pugh B.
- lenvatinib / Generic mfg.
GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy in patients with biliary tract cancers. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2076;
Patients with local advanced or metastatic BTC were given intravenous infusion of standard GemOX (85mg/m2 oxaliplatin on day 1 and gemcitabine 1000mg/m2 on a 1-8-day schedule of a 3-week treatment cycle) plus 200mg q3w of sintilimab and lenvatinib or targeted therapy based on NGS (olaparib for BRCA1/2 mutation, dasatinib for IDH1/2 mutation, afatinib for EGFR mutation, lenvatinib for PDGFR and KIT mutation, lenvatinib for FGFR/KIT mutation). In patients with advanced BTCs, the combination of GemOX plus sintilimab and lenvatinib or NGS-guided targeted therapy showed promising ORR and DCR, especially for the patients with positive PD-L1 expression and targetable gene alterations.
- lenvatinib / Generic mfg.
HRAS expression predicts Lenvatinib responsiveness in human primary gastroenteropancreatic neuroendocrine tumor cells. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2069;
In patients with advanced BTCs, the combination of GemOX plus sintilimab and lenvatinib or NGS-guided targeted therapy showed promising ORR and DCR, especially for the patients with positive PD-L1 expression and targetable gene alterations. In conclusion, we believe that the evaluation of HRAS expression and mutation might be of great interest in GEP-NET patients receiving Lenvatinib to improve patient selection.
- TheraSphere (yttrium 90 microspheres) / Boston Scientific, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical, Nexavar (sorafenib) / Bayer, Amgen
A systematic literature review of the economic evidence for transarterial radioembolization for the treatment of hepatocellular carcinoma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2062;
Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term treatment for HCC, driven by increased LYG compared to other HCC therapies.
- Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD)
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. (Available On Demand; 152a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2009;
P2
Safety analyses will be descriptive. Enrollment began August 2021.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev). (Available On Demand; 150b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2006;
P2
Patients will be stratified according to the MKI choice (cabozantinib or lenvatinib, per physician’s decision), etiology of HCC (viral vs. non-viral) and alpha-fetoprotein level ( = 400 ng/mL)...Baseline and on-treatment tumor biopsy specimens will also be collected from the initial 10 patients of each arm. The study is approved by the ethics committee and enrollment to the study will be underway by Q2/3 2022.
- Keytruda (pembrolizumab) / Merck (MSD)
First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress. (Available On Demand; 149a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2003;
P3
In part 2 (main study), approximately 850 patients will be randomly assigned 1:1 to induction with pembrolizumab plus lenvatinib plus chemotherapy (FP or mFOLFOX6 [Q2W for 6 cycles {IV oxaliplatin 85 mg/m2 plus bolus IV 5-FU 400 mg/m2 plus continuous IV 5-FU 2400 mg/m2 plus IV leucovorin 400 mg/m2 or IV levoleucovorin 200 mg/m2}]) followed by consolidation with pembrolizumab plus lenvatinib (arm 1) or pembrolizumab plus chemotherapy (FP or mFOLFOX6; arm 2)...In part 2, the dual primary end points are overall survival and progression-free survival (per RECIST v1.1 assessed by blinded independent central review [BICR]); secondary end points include objective response rate and duration of response (per RECIST v1.1 assessed by BICR) and safety and tolerability. Enrollment in this trial is ongoing.
- erfonrilimab (KN046) / Alphamab
A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results. (Available On Demand; 101) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1952;
P2
KN046+Lenvatinib demonstrated a promising efficacy in ORR and PFS and the manageable safety profile in the first-line advanced unresectable or metastatic HCC treatment. These result support the KN046 plus Lenvatinib as a potential new treatment option for this population.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab and lenvatanib combination for fibrolamellar carcinoma. (Available On Demand; 98) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1949;
Our retrospective experience with the novel immune-chemotherapy combination of NIV-LEN for FLC in an extremely rare disease with no proven systemic therapies is encouraging, especially for those who are not surgical candidates or in a surgical remission. We hope this report can inform future prospective trials in treating this deadly disease.
- Opdivo (nivolumab) / Ono Pharma, BMS
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). (Available On Demand; 94) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1945;
P2
No new safety signals were observed for the combination of nivolumab and lenvatinib. Although the study failed to reach its prespecified ORR of at least 40%, the high activity in all efficacy endpoints with a mOS of 27.1 mo supports the further investigation of the combination in HCC.
- Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials. (Available On Demand; 85) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1936;
In this network metanalysis comparing 9 landmark phase III trials in uHCC, we confirmed combination of immunotherapy with PD-1 pathway plus VEGF blockade (A+B, sintilimab+IBI305) to be associated to the highest reduction in the risk of death compared to other regimens. Within the methodological limits of this NMA, we provide evidence for the first time of comparable efficacy in terms of OS and PFS for D+T and A+B.
- Nexavar (sorafenib) / Bayer, Amgen
Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT. (Available On Demand; 66) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1917;
P3
These responses occurred irrespective of baseline characteristics. Tumor responses occurred early and were durable.
- Baize'an (tislelizumab) / BeiGene, Novartis, Nexavar (sorafenib) / Bayer, Amgen
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208. (Available On Demand; 60) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1911;
P2
Tislelizumab was investigated beyond the first-line setting, as effective second- and third-line treatment options are limited for pts with advanced HCC and there is an unmet medical need. This analysis indicates that tislelizumab is clinically active and well tolerated in pts with advanced HCC who have received prior systemic treatment with SOR/LEN.
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. (Available On Demand; 57) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1908;
This analysis indicates that tislelizumab is clinically active and well tolerated in pts with advanced HCC who have received prior systemic treatment with SOR/LEN. The present analysis conducted on a large number of non-viral HCC patients showed for the first time a significant survival benefit from lenvatinib over atezolizumab plus bevacizumab, in particular in patients with NAFLD/NASH-related HCC.
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data: For a patient with met RCC, with prior IO/IO and then cabozantinib, is there a role for lenvatinib/everolimus combo? Retrospective data not amazing, but some motivated and educated patients asking for it. Thoughts from the experts? @DrChoueiri @Uromigos @montypal (Twitter) - Apr 27, 2022
- Nexavar (sorafenib) / Bayer, Amgen
Combination of transarterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) compared to TACE alone as bridging therapy transplant recipients with hepatocellular carcinoma: An update. () - Apr 27, 2022 - Abstract #ASCO2022ASCO_2137;
P2
We have found that using TandS is generally well tolerated and demonstrated improved OS compared to TA in patients with unresectable HCC. A prospective clinical study (NCT05171335) is ongoing at our institution to further investigate this concept.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Clear cell carcinoma of the endometrium. (Pubmed Central) - Apr 27, 2022
Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma.
- || Review, Journal: Advanced RAI-refractory thyroid cancer: an update on treatment perspectives. (Pubmed Central) - Apr 27, 2022
For radioiodine (RAI) refractory DTCs ongoing research aims to identify agents that may restore RAI-avidity via redifferentiation protocols (vemurafenib or dabrafenib and trametinib) or combination treatments...The present review focuses on the molecular landscape of DTC, the approved targeted therapies as well as the mechanisms of drug resistance. Furthermore, it points to the ongoing research and the future perspectives for the development of more efficient drugs for DTC.